AAPL $348.22 +1.29% ▲ ACN $258.74 +8.21% ▲ ADBE $270.55 +6.47% ▲ ADEA $21.27 -3.64% ▼ ADIG $16.42 -0.79% ▼ ADP $307.94 +4.56% ▲ ADSK $254.95 +4.36% ▲ AEHR $55.65 -9.79% ▼ AEVA $9.88 -5.90% ▼ AGYS $120.07 +3.49% ▲ AI $12.03 +2.34% ▲ AIP $19.09 -8.92% ▼ ALAB $257.82 -8.57% ▼ ALKT $15.95 +5.63% ▲ ALNT $86.18 -11.57% ▼ AMBA $63.12 -2.82% ▼ AMBQ $49.66 -4.41% ▼ AMD $507.93 -6.03% ▼ AMPL $17.07 +4.92% ▲ AMZN $250.38 -4.22% ▼ ANET $171.02 -6.42% ▼ AOSL $22.30 -6.46% ▼ APLD $19.09 -7.46% ▼ APP $264.28 -0.65% ▼ APPN $51.15 +5.64% ▲ APPS $9.97 -3.72% ▼ ARM $210.10 -5.53% ▼ ARRY $3.30 -3.23% ▼ ARW $209.49 -4.38% ▼ ASML $1,560.54 -5.42% ▼ AAPL $348.22 +1.29% ▲ ACN $258.74 +8.21% ▲ ADBE $270.55 +6.47% ▲ ADEA $21.27 -3.64% ▼ ADIG $16.42 -0.79% ▼ ADP $307.94 +4.56% ▲ ADSK $254.95 +4.36% ▲ AEHR $55.65 -9.79% ▼ AEVA $9.88 -5.90% ▼ AGYS $120.07 +3.49% ▲ AI $12.03 +2.34% ▲ AIP $19.09 -8.92% ▼ ALAB $257.82 -8.57% ▼ ALKT $15.95 +5.63% ▲ ALNT $86.18 -11.57% ▼ AMBA $63.12 -2.82% ▼ AMBQ $49.66 -4.41% ▼ AMD $507.93 -6.03% ▼ AMPL $17.07 +4.92% ▲ AMZN $250.38 -4.22% ▼ ANET $171.02 -6.42% ▼ AOSL $22.30 -6.46% ▼ APLD $19.09 -7.46% ▼ APP $264.28 -0.65% ▼ APPN $51.15 +5.64% ▲ APPS $9.97 -3.72% ▼ ARM $210.10 -5.53% ▼ ARRY $3.30 -3.23% ▼ ARW $209.49 -4.38% ▼ ASML $1,560.54 -5.42% ▼

Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?

October 7, 2026 · by TPW Pipeline

Director Paul A. Keel purchased 4,701 shares of The Cooper Companies, Inc. (NASDAQ:COO) on Sept. 11, 2026, according to a recent SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price ($53.18); post-transaction value based on Sept. 11, 2026 market close ($53.91).

The Cooper Companies is a global medical device manufacturer with approximately 15,000 employees and a market capitalization of $10.4 billion, positioning it as a significant player in the ophthalmic and vision care sector. The company’s dual-segment strategy–combining contact lens innovation through CooperVision with surgical device offerings through CooperSurgical–provides diversified revenue streams and cross-selling opportunities within the eye care continuum. With trailing twelve-month (TTM) revenues of $4.2 billion and net income of $570.3 million, Cooper maintains a competitive edge through its extensive product portfolio addressing multiple vision correction modalities and its established relationships with eye care professionals globally.

Continue reading

Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.